Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash Flows from Operating Activities
Net income	$ 9,884	$ 1,757
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	6,108	5,951
Gain on sale of bioplastics manufacturing business	0	(1,453)
Loss on sale of assets, net	163	0
Share based compensation	271	763
Equity method investment (earnings) loss	(5,666)	871
Changes in operating assets and liabilities:
Restricted cash	0	12
Receivables, net	(6,916)	4,168
Inventory	2,970	(4,575)
Prepaid expenses	(1,249)	(1,145)
Refundable income taxes	290	7
Accounts payable	(3,499)	(781)
Accounts payable to affiliate, net	2,064	(4,008)
Accrued expenses	(968)	1,049
Deferred credit	173	(175)
Accrued retirement health and life insurance benefits and other noncurrent liabilities	(331)	(480)
Other	(417)	0
Net cash provided by operating activities	2,877	1,961
Cash Flows from Investing Activities
Additions to property and equipment	(3,594)	(1,757)
Proceeds from sale of bioplastics manufacturing business	0	2,797
Net cash provided by (used in) investing activities	(3,594)	1,040
Cash Flows from Financing Activities
Purchase of treasury stock	(537)	0
Payment of dividends	(907)	(916)
Principal payments on long-term debt	(771)	(855)
Proceeds from revolving credit facility	34,683	59,036
Payments on revolving credit facility	(33,674)	(60,266)
Loan fees incurred with borrowings	(51)	0
Net cash used in financing activities	(1,257)	(3,001)
Decrease in cash and cash equivalents	(1,974)	0
Cash and cash equivalents, beginning of year	2,857	0
Cash and cash equivalents, end of period	$ 883	$ 0